ReshuGupta

Market Overview

NAFLD's diagnosis is of particular significance due to the chances of its moving to more severe stages. In addition, in early-stage diagnosis instances, the use of specific strategies such as growing physical exercise and dietary modification may avoid unpleasantness of the disease. Except in more severe stages of the disease, like non-alcoholic steatohepatitis (NASH), it's still necessary to detect it as soon as possible because of the risk for cirrhosis progression.

Get Free Sample copy@ https://www.marketresearchfuture.com/sample_request/7984

Biomarkers are important for testing and treatment approaches for fatty liver disease cases and for faster diagnosis of potentially life threatening NASH and NAFLD. This will allow for the diagnosis and treatment of disease using a clear biomarker blood test, thereby preventing a biopsy of the liver. Managing the inherent comorbidities that produce NASH syndrome is possible, and the natural history of this daunting disease should increase. Furthermore, biomarker approaches will interface work in biomedicine.

The global market for non-alcoholic steatohepatitis biomarkers is projected to witness a 20.92 percent CAGR and is expected to hit the US$1.960.4 million mark by 2024. The key factors that pave the way for the growth of the worldwide market for non-alcoholic steatohepatitis biomarkers are the expanding presence of NASH, growing need for non-invasive diagnostic testing and awareness-raising campaigns. On the opposite, the existence of stringent rules for the certification of biomarkers by the United States FDA is expected to slow the growth of the market during the forecast period.

Market Highlights

The Global Non-Alcoholic Steatohepatitis Biomarkers Market is Expected to Register a CAGR of 20.92% and is Anticipated to Reach USD 1,960.4 Million by 2024. Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD), which is characterized by liver inflammation and damage caused by a buildup of fat in the liver. Currently, there are no noninvasive diagnostic tools approved for non-alcoholic steatohepatitis.

Growing prevalence of NASH, increasing demand for non-invasive diagnostic tests, and rising initiatives for creating awareness are some major factors propelling the growth of the market. Additionally, the rising prevalence of diabetes and obesity is likely to support market growth. On the hand, the presence of stringent regulations by the US FDA for the qualification of biomarkers is anticipated to restrict the market growth during the assessment period.

Segment Analysis

The global non-alcoholic steatohepatitis biomarkers market has been segmented by into type and end user. By type, the market has been segmented into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. By end user, the market has been segmented into pharmaceutical companies and CROs, research institutes and academics, hospitals & clinics, diagnostic centers, and others.

Market Players

Market Research Future (MRFR) recognizes the following companies as the key players in the global non-alcoholic steatohepatitis biomarkers market that includes are BioPredictive (France), Celerion (US), Cisbio (France), Echosens (France), Enterome (France), GENFIT (France), Laboratory Corporation of America Holdings (US), NGM Biopharmaceuticals (US), One Way Liver, SL (Spain), Pacific Biomarkers (US), Prometheus Laboratories Inc (US), Perspectrum Diagnostics Ltd (UK), Quest Diagnostics, Regulus Therapeutics, Inc. (US), Siemens Healthineers (Germany), Shenzhen New Industries Biomedical Engineering Co., Ltd (China), and Xeptagen SpA (Italy)

Access Report Details @ https://www.marketresearchfuture.com/reports/non-alcoholic-steatohepatitis-biomarkers-market-7984

Regional Analysis

Geographically, the Americas is expected to dominate the global non-alcoholic steatohepatitis biomarkers market. The growth in this region can be attributed to the favorable government initiatives, the presence of sophisticated healthcare infrastructure, and rising prevalence of diabetes, fatty liver disease, and obesity. Europe is anticipated to hold the second position in the global market owing to the factors such as growing incidence of NASH, increasing prevalence of obesity and diabetics, and increasing research and development on liver diseases. In the Asia-Pacific region, the market growth is mainly due to the factors such as the presence of a large patient base, increase in healthcare spending, and availability of skilled healthcare personnel. The Middle East and Africa is anticipated to register the lowest share in the global market. In the African region, the market is likely to be negatively affected by factors such as poor healthcare infrastructure, less disposable income, limited awareness about liver diseases, including NASH.

Key Findings of the Study:

• Global Non-Alcoholic Steatohepatitis Biomarkers Market is projected to reach USD 1,960.4 million by 2024 with 92% CAGR during the review period of 2019 to 2024.

• Americas accounted for the largest share in the region due to the growing demand of non-invasive diagnostics for NASH.

• The pharmaceutical companies and CROs segment accounted for the largest share, holding a market value of USD 226.7 million in 2018.